Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

McGill University

$60,570.00

Probabilistic segmentation of multiple sclerosis lesions brain images

EF 2013-14

Résumé
Multiple sclerosis (MS) is the most common neurological disease of young adults, affecting approximately50,000 people in Canada. The disease is characterized by transient attacks on the central nervous system and results in numbness or weakness of a limb, in coordination, vertigo or visual dysfunction. At present there is no cure. Over the last decade, a number of new therapies have been approved for clinical use based primarily on demonstration of their ability to reduce the number of new lesions. These drugs reduce the number of attacks by 30-50%. Evaluation of newer, more efficient treatments requires clinical trails where the 'burden of disease' is measured by identification of new lesions seen in magnetic resonance imaging (MRI). The state of the art for lesion identification in the pharmaceutical industry consists of subjective manual or semi-manual procedures. This process is subject to inter- and intra-observer variability that diminishes the statistical power to detect a drug effect. The goal of this project is to develop robust, accurate and fully automatic tissue classification techniques that can identify healthy and diseased tissues when applied to real clinical MRI. This includes accurately detecting active lesions in MRI of patients injected with contrast agents, such as Gadolinium, as well as accurate and precise identification of new, enlarging and resolving MS lesions in longitudinal MRI. Efficient successful drug development would benefit from such a technique because the improved statistical power to detect change can be used to diminish the number of subjects required or reduce the amount of time required to detect a treatment effect in a clinical trials (or both). In either case, trial costs are reduced, thus enabling the evaluation more candidate treatments. This procedure would also benefit academic research laboratories for the analysis of MRI data to further understand the disease process in MS in order to find finding better, more efficient treatments.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
411455-2010
Name nom
Arbel, Tal
Department département
Electrical and Computer Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2010
Award amount
60570
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
3
Nb partie
3
Application title
Probabilistic segmentation of multiple sclerosis lesions brain images
Keyword
NSERC
Application summary
Multiple sclerosis (MS) is the most common neurological disease of young adults, affecting approximately50,000 people in Canada. The disease is characterized by transient attacks on the central nervous system and results in numbness or weakness of a limb, in coordination, vertigo or visual dysfunction. At present there is no cure. Over the last decade, a number of new therapies have been approved for clinical use based primarily on demonstration of their ability to reduce the number of new lesions. These drugs reduce the number of attacks by 30-50%. Evaluation of newer, more efficient treatments requires clinical trails where the 'burden of disease' is measured by identification of new lesions seen in magnetic resonance imaging (MRI). The state of the art for lesion identification in the pharmaceutical industry consists of subjective manual or semi-manual procedures. This process is subject to inter- and intra-observer variability that diminishes the statistical power to detect a drug effect. The goal of this project is to develop robust, accurate and fully automatic tissue classification techniques that can identify healthy and diseased tissues when applied to real clinical MRI. This includes accurately detecting active lesions in MRI of patients injected with contrast agents, such as Gadolinium, as well as accurate and precise identification of new, enlarging and resolving MS lesions in longitudinal MRI. Efficient successful drug development would benefit from such a technique because the improved statistical power to detect change can be used to diminish the number of subjects required or reduce the amount of time required to detect a treatment effect in a clinical trials (or both). In either case, trial costs are reduced, thus enabling the evaluation more candidate treatments. This procedure would also benefit academic research laboratories for the analysis of MRI data to further understand the disease process in MS in order to find finding better, more efficient treatments.